The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Eli Lilly’s stock fell by 2.3% to close at 4:35 PM ET in after-hours trading, while Novo Nordisk’s American depositary receipts saw a decrease of 1.7%. This development came as a surprise to investors ...

Extending coverage for the medications through Medicare could cost $35 billion over nine years, a congressional analysis ...

Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade ...

Medicare delays decision on obesity drug coverage, impacting millions of seniors and big weight-loss drugmakers like Eli ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.

Telehealth company Ro will offer single-dose vials of Eli ... and weight management. Latterly, it has also started to offer compounded versions of Novo Nordisk's GLP-1 agonist drug semaglutide ...

NICE has recommended Lilly’s new soft tissue sarcoma treatment Lartruvo for use on the NHS, only the second drug to be funded ... Patient groups have joined the company in heralding the ...